Veracyte Soars on Strong Earnings, Eyes Future with New Cancer Tests

SOUTH SAN FRANCISCO, CA – February 25, 2026 – Veracyte, Inc. (Nasdaq: VCYT) delivered a powerful statement to investors and the healthcare industry this week, reporting fourth-quarter and full-year 2025 financial results that significantly surpassed analyst expectations. The cancer diagnostics company showcased remarkable profitability and robust double-digit growth, sparking a positive reaction in its stock and reinforcing its position as a leader in the precision oncology market.

Veracyte announced fourth-quarter revenue of $140.6 million, a 19% increase from the same period in 2024, comfortably beating Wall Street consensus estimates that topped out around $138.7 million. The real headline, however, was its profitability. The company posted a non-GAAP diluted earnings per share (EPS) of $0.53, crushing analyst forecasts that had ranged from $0.22 to $0.41. This impressive earnings beat, coupled with a staggering 705% year-over-year increase in GAAP net income to $41.1 million for the quarter, sent a clear signal of the company's operational strength and market traction. Following the announcement, Veracyte's stock saw an uptick in after-hours trading, reflecting investor confidence in the company's performance and future outlook. Analyst sentiment remains strong, with a majority maintaining a "Buy" rating and a consensus price target suggesting significant upside.

“We delivered an exceptional finish to 2025, with strong double-digit growth across both Decipher and Afirma and more than 45,000 patients served with our core testing business in the quarter,” said Marc Stapley, Veracyte’s chief executive officer, in the company's press release. “We are achieving this growth while maintaining best-in-class profitability, with more than $50 million of cash generated from operations in the quarter.”

Powering Growth with Core Diagnostics

The engine behind Veracyte’s stellar performance is the sustained, high-growth trajectory of its core testing portfolio, particularly the Decipher and Afirma genomic classifiers. Testing revenue for the fourth quarter climbed 21% to $135.8 million, accounting for the vast majority of the company's total income.

The Decipher franchise, which provides crucial risk assessment for prostate and bladder cancers, was the standout performer. Decipher revenue surged by 27% in the fourth quarter to $85.6 million, with test volume growing 21% to approximately 27,200. This indicates not only strong demand but also increasing adoption by clinicians who rely on the test to guide treatment decisions for patients. For the full year, Decipher revenue grew an impressive 27% to $310.7 million.

Meanwhile, the Afirma classifier, used to assess indeterminate thyroid nodules, also posted solid gains. Afirma revenue grew 16% to $47.9 million in the fourth quarter, with a 12% increase in test volume. This growth is particularly noteworthy as the company successfully completed the transition of all Afirma samples to its v2 transcriptome platform. This strategic move is designed to improve testing efficiency, reduce the number of indeterminate results, and provide a scalable platform for future product launches.

This robust growth was achieved with remarkable financial discipline. Veracyte’s non-GAAP gross margin expanded to 75.1% in the fourth quarter, a significant improvement from 69.3% in the prior year. The company's adjusted EBITDA margin reached 30.1%, far exceeding its own long-term target of 25% and demonstrating a highly efficient and profitable business model. The company ended the year in a formidable financial position, with $412.9 million in cash, cash equivalents, and short-term investments, bolstered by generating $136.3 million in cash from operations in 2025.

An Innovation Pipeline Poised for Impact

While celebrating its 2025 success, Veracyte is firmly focused on the future. The company is set to broaden its impact on the cancer care continuum with two significant product launches planned for 2026. The introduction of its Prosigna breast cancer test as a laboratory developed test (LDT) and the launch of its TrueMRD minimal residual disease test are expected to open new avenues for growth and expand the company's clinical reach.

The TrueMRD test, in particular, represents a strategic entry into one of the fastest-growing segments of the oncology diagnostics market. The test is designed to detect lingering cancer cells after treatment, a critical tool for monitoring treatment response and predicting recurrence. Veracyte has already highlighted the inclusion of its TrueMRD Muscle-Invasive Bladder Cancer (MIBC) test in a major clinical trial, with data anticipated at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).

Veracyte's commitment to building a powerful evidence-generation engine is further underscored by its significant presence at the ASCO GU meeting. The company announced that over 15 abstracts featuring its Decipher Prostate and Decipher Bladder tests will be presented. This includes key data from the SURE-02, NURE-combo, and BLASST-01 trials, which could further solidify the clinical utility of these tests and drive their inclusion in standard-of-care guidelines.

Strategic Maneuvers for Sustained Leadership

Veracyte's strong financial report also sheds light on its strategic agility in managing its global operations and portfolio. The reported decrease in biopharmaceutical and other revenue was attributed to the restructuring and liquidation proceedings of Veracyte SAS, a French subsidiary. While this resulted in a short-term revenue dip in that segment, the move appears to be part of a broader strategy to streamline operations and focus resources on its highest-growth opportunities, namely its core U.S. testing business and new product pipeline.

By managing its operating expenses effectively and focusing investment where it matters most, Veracyte has built a resilient and scalable business. The company reiterated its optimistic outlook for 2026, guiding for total revenue between $570 million and $582 million, which represents 10% to 13% growth. This guidance, driven primarily by an expected 14% to 16% growth in its core testing business, demonstrates management's confidence in its ability to maintain momentum. This forward-looking guidance notably excludes any potential contribution from its new tests, suggesting the possibility of further upside as Prosigna LDT and TrueMRD gain traction in the market. With a fortified balance sheet, a proven growth strategy, and a pipeline of innovative diagnostics, Veracyte is well-positioned to continue its mission of transforming cancer care for patients around the world.